These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 10023504)

  • 41. Plasma oxytocin changes and anti-obsessive response during serotonin reuptake inhibitor treatment: a placebo controlled study.
    Humble MB; Uvnäs-Moberg K; Engström I; Bejerot S
    BMC Psychiatry; 2013 Dec; 13():344. PubMed ID: 24359174
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Obsessive-compulsive disorder, frontostriatal system and the effect of the serotonergic system].
    Baving L; Schmidt MH
    Z Kinder Jugendpsychiatr Psychother; 2000 Feb; 28(1):35-44. PubMed ID: 10746297
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pulse-loaded intravenous clomipramine in treatment-resistant obsessive-compulsive disorder.
    Koran LM; Aboujaoude E; Ward H; Shapira NA; Sallee FR; Gamel N; Elliott M
    J Clin Psychopharmacol; 2006 Feb; 26(1):79-83. PubMed ID: 16415712
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clomipramine demethylation rate is important on the outcome of obsessive-compulsive disorder treatment.
    Marcourakis T; Bernik MA; Lotufo Neto F; Gedanke Shavitt R; Gorenstein C
    Int Clin Psychopharmacol; 2015 Jan; 30(1):43-8. PubMed ID: 25279584
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fluvoxamine combination therapy with tropisetron for obsessive-compulsive disorder patients: A placebo-controlled, randomized clinical trial.
    Shalbafan M; Malekpour F; Tadayon Najafabadi B; Ghamari K; Dastgheib SA; Mowla A; Shirazi E; Eftekhar Ardebili M; Ghazizadeh-Hashemi M; Akhondzadeh S
    J Psychopharmacol; 2019 Nov; 33(11):1407-1414. PubMed ID: 31575326
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial.
    Riddle MA; Reeve EA; Yaryura-Tobias JA; Yang HM; Claghorn JL; Gaffney G; Greist JH; Holland D; McConville BJ; Pigott T; Walkup JT
    J Am Acad Child Adolesc Psychiatry; 2001 Feb; 40(2):222-9. PubMed ID: 11211371
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder.
    Diniz JB; Shavitt RG; Fossaluza V; Koran L; Pereira CA; Miguel EC
    J Clin Psychopharmacol; 2011 Dec; 31(6):763-8. PubMed ID: 22020357
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.
    Erzegovesi S; Guglielmo E; Siliprandi F; Bellodi L
    Eur Neuropsychopharmacol; 2005 Jan; 15(1):69-74. PubMed ID: 15572275
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fluvoxamine in obsessive-compulsive disorder: similar efficacy but superior tolerability in comparison with clomipramine.
    Mundo E; Rouillon F; Figuera ML; Stigler M
    Hum Psychopharmacol; 2001 Aug; 16(6):461-468. PubMed ID: 12404554
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparing the Effects of a Herbal Drug based on
    Noras MR; Soltanifar A; Salari R; Jarahi L; Abrishami MH
    Curr Drug Discov Technol; 2022; 19(5):e240622206368. PubMed ID: 35748547
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacologic therapy of obsessive compulsive disorder.
    DeVeaugh-Geiss J
    Adv Pharmacol; 1994; 30():35-52. PubMed ID: 7833296
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictive value of obsessive-compulsive personality disorder in antiobsessional pharmacological treatment.
    Cavedini P; Erzegovesi S; Ronchi P; Bellodi L
    Eur Neuropsychopharmacol; 1997 Feb; 7(1):45-9. PubMed ID: 9088884
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dopamine blocking activity of clomipramine in patients with obsessive-compulsive disorder.
    Austin LS; Lydiard RB; Ballenger JC; Cohen BM; Laraia MT; Zealberg JJ; Fossey MD; Ellinwood EH
    Biol Psychiatry; 1991 Aug; 30(3):225-32. PubMed ID: 1832972
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial.
    Goodman WK; Kozak MJ; Liebowitz M; White KL
    Int Clin Psychopharmacol; 1996 Mar; 11(1):21-9. PubMed ID: 8732310
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders.
    Figgitt DP; McClellan KJ
    Drugs; 2000 Oct; 60(4):925-54. PubMed ID: 11085201
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacologic treatment of obsessive-compulsive disorder: comparative studies.
    Flament MF; Bisserbe JC
    J Clin Psychiatry; 1997; 58 Suppl 12():18-22. PubMed ID: 9393392
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial.
    Diniz JB; Shavitt RG; Pereira CA; Hounie AG; Pimentel I; Koran LM; Dainesi SM; Miguel EC
    J Psychopharmacol; 2010 Mar; 24(3):297-307. PubMed ID: 19164490
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics.
    McDougle CJ; Goodman WK; Leckman JF; Lee NC; Heninger GR; Price LH
    Arch Gen Psychiatry; 1994 Apr; 51(4):302-8. PubMed ID: 8161290
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clomipramine in obsessive-compulsive disorder: clinical response and plasma levels.
    Mavissakalian MR; Jones B; Olson S; Perel JM
    J Clin Psychopharmacol; 1990 Aug; 10(4):261-8. PubMed ID: 2286699
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Citalopram for treatment-resistant obsessive-compulsive disorder.
    Pallanti S; Quercioli L; Paiva RS; Koran LM
    Eur Psychiatry; 1999 Apr; 14(2):101-6. PubMed ID: 10572334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.